Epstein-Barr virus latent membrane protein 2 peptide-MHC class I complex (EBV LMP2-MHC I)

The Epstein-Barr virus latent membrane protein 2 (LMP2) peptide-MHC class I complex is a critical immunological target for treating EBV-associated malignancies. LMP2, particularly the LMP2A isoform, is expressed during viral latency and plays a significant role in maintaining B-cell survival and promoting oncogenesis in epithelial and lymphoid cells (UniProt P13285). These proteins are processed by the intracellular proteasome into short peptide fragments, which are then loaded onto MHC class I molecules and presented on the cell surface for surveillance by CD8+ T cells (PubMed: 15141005). Because LMP2 is consistently expressed in EBV-related cancers such as nasopharyngeal carcinoma and Hodgkin lymphoma, these peptide-MHC complexes serve as highly specific viral antigens that distinguish malignant cells from healthy tissue (PubMed: 25231357). Therapeutic strategies targeting this complex include adoptive T-cell therapies, such as TCR-engineered T cells and EBV-specific cytotoxic T lymphocytes (CTLs), as well as therapeutic vaccines designed to boost the endogenous immune response (PubMed: 30633422). By specifically recognizing these viral epitopes, the immune system can selectively eliminate infected or malignant cells, offering a precision medicine approach for EBV-driven diseases.

Other names

LMP2 peptide-HLA complexEBV LMP2A/B epitopesLatent membrane protein 2 peptide-MHCEBV LMP2-HLA-A*02:01 complexLMP2-derived peptide-MHC class I

Recognition by T-cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes, leading to the targeted lysis of EBV-infected or malignant cells presenting the viral peptide.